CMDv/BPG/012 BEST PRACTICE GUIDE for Informed …
3. legal framework 4. references and related documents 5. general 6. description of the procedure annex 1: template for letter of access for an application under
Download CMDv/BPG/012 BEST PRACTICE GUIDE for Informed …
Information
Domain:
Source:
Link to this page:
Documents from same domain
Guidance on the homeopathic medicinal products …
www.hma.euSPECIFIC GUIDANCE ON MODULE 3 OF THE HOMEOPATHIC MEDICINAL PRODUCTS DOSSIER Introduction With the implementation of Directive 2001/83/EC as amended all Member States of the
Packaging ‘blue-box’ requirements for products …
www.hma.euCMDv GUI-027 _ addition CP EMA/CMDv/391895/2012 Page 1 of 42 . CMDv-GUI-27 EMA/CMDv/391895/2012 . Version 072904/101/2014 . Packaging ‘blue-box’ requirements for products authorised via
Packaging ‘blue-box’ requirements and additional ...
www.hma.euLegal Status For medicinal products restricted to special prescription (narcotics), a number code assigned by the Minister of Health and a double red line are mandatory.
BEST PRACTICE GUIDE for Veterinary Decentralised …
www.hma.euBEST PRACTICE GUIDE . for . Veterinary Decentralised Procedure (DCP) Edition number: 05 . Edition date: 7 November 2013 . Implementation date: 6 February 2006
CONSULTATION WITH TARGET PATIENT GROUPS …
www.hma.euconsultation with target patient groups - meeting the requirements of article 59(3) without the need for a full test - recommendations for bridging
CMD(h) BEST PRACTICE GUIDE ON THE …
www.hma.euBPG on the Processing of Renewals in the Mutual Recognition and Decentralised Procedures Rev.5, November 2008 Page 2/11 The principle applies that the marketing authorisation holder may apply for a renewal earlier than
DECENTRALISED PROCEDURE MEMBER STATES’ …
www.hma.euDECENTRALISED PROCEDURE MEMBER STATES’ STANDARD OPERATING PROCEDURE October 2005 Final Revision 1 November 2007 TABLE OF CONTENTS Abbreviations.....1
FLOW CHART OF THE DECENTRALISED …
www.hma.euFlow Chart of the Decentralised Procedure 25 July 2005 Page 1/3 FLOW CHART OF THE DECENTRALISED PROCEDURE 1. Issue The Heads of Medicines Agencies (HMA) together with MRFG and VMRFG have
CMDv/BPG/003 Best Practice Guide For The Repeat …
www.hma.euIn case of electronic submissions the “Guideline on the specifications for provision of an electronic submission (esubmission) for a veterinary medicinal product- should be ”
FLOW CHART FOR THE MUTUAL RECOGNITION …
www.hma.euFLOW CHART FOR THE MUTUAL RECOGNITION PROCEDURE May 2007 Approx. 90 days before submission to CMS Applicant requests RMS to update Assessment Report (AR) and allocate
Related documents
Guideline on the specifications for provision of an ...
esubmission.ema.europa.euGuideline on specification for veterinary e-submissions Page 3 of 18 Introduction This Guidance Document is intended to assist applicants and regulators with submissions of …
Guideline on Active Substance Master File Procedure
www.ema.europa.euThe main objective of the Active Substance Master File (ASMF ) procedure, formerly known as the European Drug Master File (EDMF) procedure, is to allow valuable confidential intellectual property or
Appendix 8 Data Requirements for New Medicine …
www.medsafe.govt.nzcontrol of starting materials, reagents, catalysts, solvents and any isolated intermediates, as well as any subsequent processing (eg, milling) of the bulk substance.
STABILITY TESTING OF ACTIVE SUBSTANCES AND …
www.who.intWorking document QAS/06.179 page 2 REGIONAL GUIDELINE FOR THE WHO EASTERN MEDITERRANEAN REGION STABILITY TESTING OF ACTIVE SUBSTANCES AND PHARMACEUTICAL PRODUCTS DRAFT 2.0 19 April 2006 This guideline has been developed during the WHO EMRO Consultation on Regional
ACTIVE PHARMACEUTICAL INGREDIENTS …
apic.cefic.orgAPIC_eCTD How to Do Page 4 INTRODUCTION eCTD is a topic of increasing interest in the pharmaceutical environment. In the past, the main focus for regulatory authorities was eCTD submissions sent via MAAs.
Forced degradation studies – comparison between …
dgra.dePage 1 1. Introduction and scope Forced degradation is an exposure of the drug substance or drug product to different stress conditions (more severe than accelerated conditions) [1] which results in relevant